ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "joint damage and rheumatoid arthritis (RA)"

  • Abstract Number: 2506 • 2018 ACR/ARHP Annual Meeting

    The Joint Disease Burden in Patients with Secondary Sjögren’s Syndrome and RA Compared to Patients with RA Only

    Evo Alemao1, Yogesh Saini2, Ying Bao1, Aarti Rao2, Christine K Iannaccone3, Michael E Weinblatt3 and Nancy A. Shadick3, 1Bristol-Myers Squibb, Princeton, NJ, 2Mu Sigma, Bangalore, India, 3Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Secondary Sjögren’s syndrome (sSS) is considered a poor prognostic factor in RA and is a common extra-articular manifestation of RA. We estimated prevalence of…
  • Abstract Number: 450 • 2017 ACR/ARHP Annual Meeting

    Disease Duration and Withdrawal of Biologic Agents Predict Radiological Progression in a Cohort of Rheumatoid Arthritis Patients in Latin America. a Real World Study

    Rocio V. Gamboa-Cardenas1,2, Manuel Ugarte-Gil3, Francisco Zevallos4, Mariela Medina4, Claudia Elera-Fitzcarrald4, Victor Pimentel-Quiroz4, Cristina Reategui-Sokolova4, Omar Sarmiento-Velasquez4, Zoila Rodriguez-Bellido4, José Alfaro4, Mariano Cucho-Venegas4, Cesar A. Pastor-Asurza4 and Risto Perich-Campos5, 1Rheumatology, Hospital Guillermo Almenara, EsSalud, Lima, Peru, 2Universidad Nacional Mayor de San Marcos, Lima, Peru, 3Peru, GLADEL, Lima, Peru, 4Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, 5Rheumatology, Hospital Guillermo Almenara Irigoyen, Lima, Peru

    Background/Purpose: Optimal management of Rheumatoid Arthritis (RA) based in identification of patients with risk factors for Joint Damage (JD) progression, is a main strategy, but…
  • Abstract Number: 454 • 2017 ACR/ARHP Annual Meeting

    Soluble Urokinase Plasminogen Activator Receptor (suPAR) Correlates with Disease Activity in Early Rheumatoid Arthritis and Reflects Joint Damage over Time

    Helena Enocsson1, Alf Kastbom1, Tanja Lukic1, Christopher Sjöwall2, Thomas Skogh1 and Jonas Wetterö1, 1Rheumatology, Division of Neuro and Inflammation Sciences, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, Linköping, Sweden, 2Department of Clinical and Experimental Medicine, Linköping University, Sweden, Linköping, Sweden

    Background/Purpose: The urokinase plasminogen activator receptor (uPAR) is expressed on various cell types and plays important roles in proteolysis, migration and adhesion. Receptor shedding yields…
  • Abstract Number: 1028 • 2017 ACR/ARHP Annual Meeting

    Association of a Non-Synonymous, Loss-of-Function, Variant in NOD2 with Reduced Tissue Damage in ACPA +Ve RA

    Ricardo Segurado1, Denis Shields1, Rachel Knevel2, Annette H.M. van der Helm-van Mil3, Tom W.J. Huizinga4 and Anthony G. Wilson5, 1University College Dublin, Dublin, Ireland, 2Medical and Population Genetics Program, Broad Institute of MIT and Harvard, Cambridge, MA, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, 5UCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin, Ireland

    Background/Purpose: The functional capacity of individuals with rheumatoid arthritis (RA) is related to the severity of damage to bone and cartilage within joints. This is…
  • Abstract Number: 1353 • 2017 ACR/ARHP Annual Meeting

    Is Joint Damage Due to Secondary Osteoarthritis (OA) Clinically As Important As Inflammation in Contemporary Management of Rheumatoid Arthritis (RA)?

    Theodore Pincus1, Isabel Castrejón2, Kathryn A. Gibson3 and Joel A Block2, 1Rheumatology, Rush University Medical Center, Chicago, IL, 2Division of Rheumatology, Rush University Medical Center, Chicago, IL, 3Liverpool Hospital, Sydney, Australia, Sydney, Australia

    Background/Purpose: Measures to assess patients with rheumatoid arthritis (RA) reflect primarily inflammatory activity in patients who meet inclusion criteria for selection into clinical trials. However,…
  • Abstract Number: 2964 • 2017 ACR/ARHP Annual Meeting

    Structural Damage in Patients with Very Early RA Is Predicted with Clinical Measures of Baseline Disease Activity: DAS28 (CRP), SDAI, M-DAS28 and RAPID3 but Not CDAI

    Edward C. Keystone1, H Ahmad2, Yusuf Yazici3, X Liu2 and MJ Bergman4, 1University of Toronto, Toronto, ON, Canada, 2Bristol-Myers Squibb, Princeton, NJ, 3New York University School of Medicine, New York, NY, 4Drexel University College of Medicine, Philadelphia, PA

    Background/Purpose: Clinicians rely on time-efficient, validated disease activity assessments to help accurately predict disease progression in patients with RA. The utility of the Routine Assessment…
  • Abstract Number: 583 • 2016 ACR/ARHP Annual Meeting

    Associations of Serum Anti-Citrullinated Proteins and Cytokines with Radiographic Scores in African-American Rheumatoid Arthritis Patients

    Dongmei Sun1, William H Robinson2, Xiangqin Cui3, Vincent A. Laufer4, Maria I. Danila5, Richard J. Reynolds6, Chander Raman7, Stephanie Ledbetter8, Alexander Szalai9 and S. Louis Bridges Jr.9, 1Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 2Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, 3Biostatistics, University of Alabama at Birmingham, Birmingham, AL, 4Division of Clinical Rheumatology and Immunology, University of Alabama at Birmingham, Birmingham, AL, 5University of Alabama at Birmingham, Birmingham, AL, 6Medicine, University of Alabama at Birmingham, Birmingham, AL, 7Medicine/Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 81825 University Blvd., University of Alabama at Birmingham, Birmingham, AL, 9Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Serum anti-citrullinated proteins (ACPA, including anti-CCP antibodies) and rheumatoid factor (RF) are critical diagnostic markers for RA, and are associated with more severe radiographic…
  • Abstract Number: 644 • 2016 ACR/ARHP Annual Meeting

    Seroprevalence and Its Impact on Radiographic Damage in Korean Rheumatoid Arthritis Patients Starting Biologics

    Kichul Shin1, Seongjun Ha2, Inkyung Jung3, Hyoun-Ah Kim4 and Shin-Seok Lee5, 1Kyungnam villa #102, Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of, 2Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, The Republic of, 3Department of Biostatistics, Yonsei University College of Medicine, Seoul, Korea, The Republic of, 4Ajou University Hospital, Suwon, South Korea, 5Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Korea, The Republic of

    Background/Purpose: High titers of rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (ACCP) are poor prognostic factors for rheumatoid arthritis (RA) patients. Only few studies…
  • Abstract Number: 92 • 2015 ACR/ARHP Annual Meeting

    Variation at Interleukin-6 Receptor Gene Is Associated to Joint Damage in Rheumatoid Arthritis

    María López-Lasanta1, Antonio Julià1, Joan Maymo2, Benjamin Fernandez Gutierrez3, Inmaculada Ureña4, Francisco J. Blanco5, Juan D. Cañete6, Mercedes Alperi-López7, Alejandro Olivé8, Hector Corominas9, Jesús Tornero10, Alba Erra11, Miriam Almirall12, Nuria Palau13, Ana M. Ortiz Garcia14, Gabriela Avila13, Luis Rodriguez-Rodriguez15, Arnald Alonso1, Raül Tortosa1, Isidoro González-Alvaro16 and Sara Marsal1, 1Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, 2Rheumatology, Hospital del Mar, Barcelona, Spain, 3Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, 4Rheumatology service, Hospital Regional Universitario Carlos Haya, Malaga, Spain, 5Osteoarticular and Aging Research Lab, INIBIC–Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, 6Arthritis Unit. Rheumatology, Arthritis Unit. Rheumatology Department. Hospital Clínic, Barcelona, Spain, 7Department of Rheumatology, Hospital Universitario Central de Asturias, Asturias, Spain, 8Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, 9Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, 10Rheumatology Department, Hospital Universitario Guadalajara, Guadalajara, Spain, 11Rheumatology, Rheumatology Hospital San Rafael, Barcelona, Spain, 12Rheumatology Department, Hospital del Mar, Barcelona, Spain, 13Vall d'Hebron Hospital Research Institute, Barcelona, Spain, 14Rheumatology, H.U. La Princesa, Madrid, Spain, 15Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain, 16Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain

    Background/Purpose: Interleukin-6 (IL-6) cytokine signaling is key in Rheumatoid Arthritis (RA) pathophysiology. Blocking IL-6 receptor (IL6R) has proven to be a highly effective treatment to prevent joint…
  • Abstract Number: 104 • 2015 ACR/ARHP Annual Meeting

    A Genome-Wide Association Study Identifies SLC8A3 As a Susceptibility Locus for ACPA-Positive Rheumatoid Arthritis

    Antonio Julià1, Isidoro González-Alvaro2, Antonio Fernandez-Nebro3, Francisco Blanco4, Benjamin Fernandez Gutierrez5, Antonio Gonzalez6, Juan D. Cañete7, Joan Maymo8, Mercedes Alperi-López9, Alejandro Olivé10, Hector Corominas11, Víctor Martínez Taboada12, Alba Erra13, Simon Sanchez Fernandez14, Arnald Alonso1, María López-Lasanta1, Raül Tortosa1, S. Louis Bridges Jr.15, Jesús Tornero16 and Sara Marsal17, 1Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, 2Rheumatology Department, Hospital Universitario la Princesa, IIS-Princesa, Madrid, Spain, 3Rheumatology, Hospital Universitario Carlos Haya, Malaga, Spain, 4Rheumatology Division, Fundación Profesor Novoa Santos, A Coruna, Spain, 5Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, 6H. Clinico Universtiario de Santiago, Santiago de Compostela, Spain, 7Unitat d’Artritis, Servei de Reumatologia, Hospital Clínic de Barcelona and Institut d’Investigacions Biomèdiques August Pí i Sunyer, Barcelona, Spain, 8H del Mar, Barcelona, Spain, 9Department of Rheumatology, Hospital Universitario Central de Asturias, Asturias, Spain, 10Hospital Germans Trias i Pujol, Badalona, Spain, 11Servei de Reumatologia, Hospital Moises Broggi, Barcelona, Spain, 12Rheumatology, Hospital Marqués de Valdecilla, Santander, Spain, 13CapiCAT group (Nailfold Capillaroscopy group from the Catalan Society for Rheumatology)., Catalonia, Spain, 14Rheumatology Department, Hospital General La Mancha Centro, Ciudad Real, Spain, 15Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 16Rheumatology Department, Hospital Universitario Guadalajara, Guadalajara, Spain, 17Rheumatology Research Unit, Vall d'Hebron Hospital, Barcelona, Spain

    Background/Purpose:  Rheumatoid Arthritis (RA) patients with serum anti-citrullinated peptide antibodies (ACPA) have a strong and specific genetic background. We performed a genome-wide association study (GWAS)…
  • Abstract Number: 515 • 2015 ACR/ARHP Annual Meeting

    Are Changes in Autoantibody Levels Reflecting Change in Prognosis of Rheumatoid Arthritis?

    Manuel Unger1, Farideh Alasti1, Paul Studenic1, Josef S. Smolen2,3 and Daniel Aletaha1, 1Department of Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, 22nd Department of Medicine, Hietzing Hospital, Vienna, Austria, 3Department of Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria

    Background/Purpose: The presence of rheumatoid factor (RF) and antibodies against citrullinated peptides (ACPA) is associated with progression of joint damage in patients with rheumatoid arthritis…
  • Abstract Number: 1573 • 2015 ACR/ARHP Annual Meeting

    Plasma Pentraxin 3 Concentration Is Associated with Progression of Radiographic Joint Damage but Not with Carotid Atherosclerosis in Female Patients with Rheumatoid Arthritis: Results from a 3-Year Prospective Study

    Yu Asanuma1, Yuki Shimada2, Yoshimi Aizaki1, Kazuhiro Yokota1, Noritsune Kouzu3, Yoshitake Takebayashi4, Hisashi Noma4, Shinichi Kawai5 and Toshihide Mimura2, 1Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, 2Saitama Medical University, Saitama, Japan, 3Kouzu Orthopaedic Clinic, Chiba, Japan, 4The Institute of Statistical Mathematics, Tokyo, Japan, 5Div of Rheum/dept of Int Med, Toho Uni Sch of Med, Tokyo, Japan

    Background/Purpose: Pentraxin 3 (PTX3) plays an important role in inflammation, immunity, and atherosclerosis. Plasma PTX3 level is recognized as a marker that responds to local…
  • Abstract Number: 1582 • 2015 ACR/ARHP Annual Meeting

    Joint Damage Associated with Loss of Body Mass in Rheumatoid Arthritis

    Jose Felix Restrepo1, Inmaculada del Rincon2, Daniel Battafarano3 and Agustin Escalante4, 1Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 2Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, 3Rheumatology, San Antonio Military Medical Center, JBSA - Ft Sam Houston, TX, 4Dept. of Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX

    Background/Purpose: Body mass index (BMI) is a predictor of long-term outcome in rheumatoid arthritis and has been associated with joint damage. Our objective was to examine…
  • Abstract Number: 3102 • 2015 ACR/ARHP Annual Meeting

    Increasing Circulating Adiponectin after DMARD Initiation Is Associated with Radiographic Progression in Early Aggressive RA, Regardless of Treatment Strategy

    Jon T. Giles1, S. Louis Bridges Jr.2, James R. O'Dell3, Stacey Cofield4, George Howard5, Jeffrey R. Curtis6 and Larry W. Moreland7, 1Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, 2Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3Rheumatology, University of Nebraska Medical Center, Omaha, NE, 4School of Public Health, University of Alabama at Birmingham, Birmingham, AL, 5Biostatistics, The University of Alabama at Birmingham, Birmingham, AL, 6University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL, 7Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Higher levels of circulating adiponectin have been linked to radiographic progression in RA in observational studies, but never studied in the context of early…
  • Abstract Number: 431 • 2014 ACR/ARHP Annual Meeting

    Joint Dermal Temperature Specifically Identifies the Individual RA Patient Most Likely to Develop Radiographic Change on Sharp Score; An Exam in Less Than a Minute Can Predict Who Specifically Needs Biologic Therapy

    Maria Greenwald1, Joann Ball2 and Harold Paulus3, 1Desert Medical Advances, PALM DESERT, CA, 2rheumatology, Desert Medical Advaces, Palm Desert, CA, 3Rheumatology, UCLA, Los Angeles, CA

     Background/Purpose: Joint dermal temperature (temp) measured in less than a minute can identify specifically the individual RA patient most likely to develop radiographic change on…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology